The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

About Altos Solutions

Altos Solutions is the pioneer in secure web-based oncology-specific software applications; focusing on intuitive electronic medical records, practice management with integrated medical billing, real-time comparative analytics, and patient and provider portals. Altos Solutions is the first company in the US to offer oncology practices an oncology-specific EMR application combined with services to collect, benchmark, and analyze the data contained in these records. With an installed base of over 1,300 oncology clinicians and thousands of daily users, OncoEMR is the answer for all oncology practices from the solo practitioner oncologist, multi-location cancer centers, and hospital-based ambulatory cancer centers.

Altos Solutions Headquarter Location

5424 Sunol Blvd Suite 10-177

Pleasanton, California, 94566,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Altos Solutions

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Altos Solutions in 1 CB Insights research brief, most recently on Apr 6, 2021.

Expert Collections containing Altos Solutions

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Altos Solutions is included in 2 Expert Collections, including Health IT .


Health IT

2,531 items



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Altos Solutions News

Coming out of stealth mode, new startup Spesana reveals molecular diagnostic decision support tool

Oct 6, 2020

The new tool helps synthesize information from EHRs, payers, clinical trials and reports. Share A new oncology treatment company dubbed Spesana is emerging out of stealth mode with a new molecular diagnostic decision support tool. The platform is able to take information from a number of sources and synthesize information for providers. The way it works is Spesana’s tech can collect molecular diagnostic reports and coordinate them with EHRs, prior authorizations, payer processing, approved drugs and pathways, clinical trials and clinical literature, and scheduling, according to the startup. The team at Spesana is led by Carla Balch, whose work as president and CEO or Altos Solutions put her on the digital health map. Altos Solutions was later acquired by Flatiron Health. HIMSS20 Digital WHY IT MATTERS The new company is pitching its technology as a way to help synthesize information. “Tremendous advances are being made on nearly every front of cancer research, but it’s frankly not being felt on the front lines of care,” Balch said in a statement. “The continuity of care is being lost through too many disconnections between physicians, specialists, molecular diagnostics, payers and pharma. An evidence-based approach has been supplanted by a paperwork-based approach that has more to do with bureaucratic prowess than clinical judgement. That’s unacceptable.” Oncology care is in demand in the U.S., since there are approximately 1.8 million new cases of cancer diagnosed in the nation each year, according to the  National Cancer Institute . THE LARGER TREND Oncology care has been moving increasingly digital. Flatiron , where Balch previously worked, is an oncology HER software. The company was acquired by pharma giant Roche in 2018 for $1.9 billion. But Flatiron wasn’t the only startup looking into cancer care. Finnish company Kaiku Health created a platform that allows patients to track symptoms over time and can alert doctors or researchers with updates. In May, the startup was acquired by Swedish oncology-focused tech firm Elekta. Kaiku’s technology is expected to be integrated into Elekta's Mosaiq Oncology Information system. The oncology space also saw another large M&A when remote-monitoring and decision-support startup  Biofourmis  announced its plans to acquire Takeda Pharmaceuticals’ Gaido Health, an oncology-focused digital tool. ON THE RECORD  “It will take more than electronic medical record algorithms to move decision-making to where it’s needed,” said Balch. “As CEO of Altos Solutions, we created the first EMR-based decision support for oncology in 2008. While we were successful in moving healthcare from paper to digital records, the benefits of that process are declining without addressing the gap between reports, physicians and the EMR, not to mention the payer system. "That’s why we’ve set about working with representatives of every stakeholder group to tackle that problem. We are doing it with a new approach, joining together the relevant data sources into a more streamlined decision support process.”

  • When was Altos Solutions founded?

    Altos Solutions was founded in 2004.

  • Where is Altos Solutions's headquarters?

    Altos Solutions's headquarters is located at 5424 Sunol Blvd, Pleasanton.

  • What is Altos Solutions's latest funding round?

    Altos Solutions's latest funding round is Acquired.

  • Who are the investors of Altos Solutions?

    Investors of Altos Solutions include Flatiron Health.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.